Nexalin Technology (NXL) Debt to Equity (2021)
Nexalin Technology's quarterly Debt to Equity came in at -$0.04 in Q4 2021.
Nexalin Technology has reported Debt to Equity for 1 years, with the latest figure at -$0.04 in Q4 2021.
- For the quarter ending Q4 2021, Debt to Equity changed N/A year-over-year to -$0.04; the trailing twelve-month figure through Dec 2021 stood at -$0.04 (changed N/A YoY), and the FY2021 full-year result was -$0.04, changed N/A from the prior year.
- Debt to Equity for Q4 2021 stood at -$0.04.
- The five-year high for Debt to Equity was -$0.04 in Q4 2021, with the low at -$0.04 in Q4 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 0.65 |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 0.64 |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 0.57 |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 0.42 |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 0.06 |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 0.95 |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 0.27 |
| 10 | Nexalin Technology | 11.19 Mn | 8.48 Mn | 13,133.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -0.04 |